Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Prevention |
RCV003419069 | SCV004117913 | pathogenic | ACTA1-related disorder | 2022-12-07 | criteria provided, single submitter | clinical testing | The ACTA1 c.686T>C variant is predicted to result in the amino acid substitution p.Met229Thr. This variant (legacy nomenclature p.Met227Thr) was reported as de novo in two presumably unrelated patients with nemaline myopathy (Sparrow et al 2003. PubMed ID: 12921789; Table S1, Laing. 2009. PubMed ID: 19562689). Two other substitutions (Val, Ile) at this amino acid position have also been reported as pathogenic in seven patients, occurring de novo in all three cases in which parents were available for testing (Sparrow et al 2003. PubMed ID: 12921789; Table S1, Laing. 2009. PubMed ID: 19562689). This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. This variant is interpreted as pathogenic. |
Muscle and Diseases Team, |
RCV004587490 | SCV005038471 | pathogenic | Nemaline myopathy | 2024-03-01 | criteria provided, single submitter | research | PS2+PM1+PM2+PP2+PP3+PP5 |